A new study optimizes the probability of success for allogenic cell therapy in patients with heart failure
Researchers from the Heart Disease Research Group at the IGTP and the CIBER Cardiovascular Group both led by Dr Antoni Bayés prepare the way to optimize reparative cell therapy in heart failure patients. The study, carried out in conjunction with the Immunogenetics and Histocompatibility Laboratory and the Cell Therapy Unit of the Blood and Tissue Bank of Barcelona has studied the HLA allele and the frequency of haplotypes in a cohort of patients with heart failure as the first stage in optimizing future allogenic cell therapies for these patients.
The IGTP and la Caixa join together to promote a pioneering programme in bioimaging
On 29 January the director of the IGTP, Manel Puig and the Director General of the “la Caixa” Foundation, Jaume Giró signed an agreement to promote the 3R policy in health Research as a new paradigm in preclinical research.
This Newsletter is for information only Please check all information on the corresponding sites
The IGTP is not responsible for the content of webpages that the user can access through links in this newsletter. The IGTP cannot examine or control the content of other sites on the web, nor can it guarantee the availability, truth, accuracy, validity or legality of sites that are not its property, but that can be accessed via links.